세계의 간섬유증 치료 시장 예측 : 치료 유형, 병태, 유통 채널, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Liver Fibrosis Treatment Market is accounted for $20.71 billion in 2025 and is expected to reach $48.87 billion by 2032 growing at a CAGR of 13.05% during the forecast period. Treatment for liver fibrosis targets the reduction or reversal of scar tissue formation resulting from ongoing liver damage or inflammation. It involves managing the root cause like viral hepatitis, alcohol consumption, or nonalcoholic fatty liver alongside medications, lifestyle modifications, and supportive care to minimize further harm. Timely treatment helps preserve liver function, slows disease progression, and lowers the risk of developing cirrhosis, ultimately improving overall health and prognosis.

According to the National Institute on Alcohol Abuse and Alcoholism 2023, in 2022, about 29.5 million individuals in the United States with alcohol dependence, or 10.5% of individuals aged between 12 years and above.

Market Dynamics:

Driver:

Growing geriatric population

The increasing number of elderly individuals worldwide is significantly boosting demand for liver fibrosis treatments. Older adults are more prone to liver disorders due to age-related immune decline and long-term exposure to metabolic stressors. Conditions like obesity, diabetes, and heart disease often coexist, accelerating liver deterioration. As longevity rises, healthcare providers are seeing a growing need for therapies tailored to older patients. This trend is encouraging pharmaceutical innovation focused on safer and more effective anti-fibrotic options for seniors. Eventually, the aging demographic is expanding the treatment market and influencing the direction of clinical development.

Restraint:

Limited availability of approved anti-fibrotic drugs

Most available therapies concentrate on managing underlying causes such as viral hepatitis or fatty liver disease, rather than reversing fibrotic damage. Regulatory complexities and extended development timelines have slowed the introduction of new treatments. Many promising compounds are still in early research phases, leaving clinicians with few targeted solutions. This shortage affects patient care and restricts market expansion, particularly in high-burden regions. Until more anti-fibrotic agents receive approval, treatment options will remain constrained.

Opportunity:

Expansion of telemedicine and digital health platforms

The rise of digital health and telemedicine is opening new avenues for managing liver fibrosis. Virtual consultations allow patients to access liver specialists and receive timely care, especially in remote or underserved areas. Wearables and mobile apps can monitor liver function indicators and support medication adherence. These technologies also enable customized treatment plans and improve patient education, fostering better health outcomes. As digital healthcare becomes mainstream, liver fibrosis care is becoming more proactive and accessible. This shift is expected to drive broader adoption of innovative therapies and enhance disease management.

Threat:

Competition from alternative therapies

Alternative therapies are increasingly challenging the dominance of traditional liver fibrosis treatments. Preventive strategies like lifestyle changes, dietary interventions, and metabolic control are gaining traction as first-line approaches. Regenerative techniques and cell-based therapies also offer novel solutions that may bypass conventional drug treatments. This expanding range of options could reduce reliance on pharmacological interventions. Additionally, clinicians may be cautious about adopting new drugs if non-invasive methods prove effective.

Covid-19 Impact:

The COVID-19 pandemic had a notable effect on the Liver Fibrosis Treatment Market, causing delays in diagnostics, routine check-ups, and non-essential medical procedures. Treatment schedules were often postponed, resulting in possible disease advancement for some patients. Disruptions in supply chains hindered the availability of medicines and diagnostic tools. On the positive side, the crisis spurred the adoption of telemedicine and heightened awareness of liver health, as COVID-19's potential impact on liver function emphasized the importance of early detection and effective care.

The peroxisome proliferator segment is expected to be the largest during the forecast period

The peroxisome proliferator segment is expected to account for the largest market share during the forecast period, driven by advancements in drug discovery technologies, including high-throughput screening and molecular modelling. Emerging trends such as the development of dual and pan-PPAR agonists offer broader therapeutic benefits. Key developments include promising clinical trial results and strategic collaborations between pharmaceutical companies to accelerate innovation. Increasing prevalence of nonalcoholic steatohepatitis (NASH) and related metabolic disorders further fuels demand, positioning PPAR-based treatments as a vital segment in liver fibrosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospital pharmacies segment is predicted to witness the highest growth rate, driven by advancements in pharmaceutical dispensing technologies, such as automated drug distribution and electronic prescription systems, enhancing efficiency and accuracy. Emerging trends include integration of telepharmacy services and personalized medicine approaches for liver disease patients. Developments like hospital collaborations with pharmaceutical companies for clinical trials and early drug access programs. Rising hospitalization rates for liver-related conditions and increasing availability of advanced therapies further strengthen the role of hospital pharmacies in treatment delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to escalating cases linked to hepatitis, NASH, and alcohol-induced liver damage. Innovations in non-invasive imaging and RNA therapeutics are enhancing early diagnosis and targeted care. The market is seeing growth in digital health adoption and personalized treatment approaches. Notable progress includes new drug candidates and expanded trial activity in India, Japan, and China. Aging populations, rising health awareness, and increased government investment are fueling technological advancement and regional market growth.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to growing prevalence of NASH, NAFLD, and hepatitis, supported by robust healthcare systems and research funding. Breakthroughs in AI-driven diagnostics, non-invasive technologies, and RNA therapeutics are improving accuracy and early intervention. Trends like telemedicine and tailored treatment approaches are gaining traction. Recent progress includes new PPAR-targeting drugs, multi-modal regimens, and expanded trial networks. Rising health literacy, favourable regulations, and active pharmaceutical pipelines are driving sustained market expansion across the region.

Key players in the market

Some of the key players in Liver Fibrosis Treatment Market include Abbott Laboratories, Bristol-Myers Squibb Company, Akero Therapeutics, Hepion Pharmaceuticals, Alentis Therapeutics, Inventiva Pharma, Alnylam Pharmaceuticals, Johnson & Johnson, Astellas Pharma Inc., Novartis AG, Boehringer Ingelheim, Merck & Co., Inc., Pfizer Inc., Sanofi AG, Vertex Pharmaceuticals Incorporated, Galectin Therapeutics, Inc., Takeda Pharmaceutical Company, Gilead Sciences, Inc., Madrigal Pharmaceuticals, Inc., and GlaxoSmithKline PLC.

Key Developments:

In July 2025, Johnson & Johnson MedTech announced a strategic co-promotion agreement with Pacira BioSciences, Inc., the industry leader in the delivery of innovative, non-opioid pain therapies. The agreement expands the Company's Early Intervention portfolio with ZILRETTA(R) (triamcinolone acetonide extended-release injectable suspension) an extended-release injectable for treatment of pain related to osteoarthritis (OA) of the knee.

In June 2025, Bristol Myers Squibb and BioNTech SE announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history - a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Treatment Types Covered:

• ACE Inhibitors
• Antiviral Drugs
• Cell Therapy
• Peroxisome Proliferator
• FXR Agonists
• Targeted Therapy
• Hepatotropic Drugs
• Other Treatment Types

Conditions Covered:

• Nonalcoholic Steatohepatitis (NASH)
• Chronic Liver Diseases
• Hepatitis C
• Alcoholic Liver Disease
• Genetic Disorders
• Autoimmune Hepatitis

Distribution Channels Covered:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Liver Fibrosis Treatment Market, By Treatment Type

• 5.1 Introduction
• 5.2 ACE Inhibitors
• 5.3 Antiviral Drugs
• 5.4 Cell Therapy
• 5.5 Peroxisome Proliferator
• 5.6 FXR Agonists
• 5.7 Targeted Therapy
• 5.8 Hepatotropic Drugs
• 5.9 Other Treatment Types

6 Global Liver Fibrosis Treatment Market, By Condition

• 6.1 Introduction
• 6.2 Nonalcoholic Steatohepatitis (NASH)
• 6.3 Chronic Liver Diseases
• 6.4 Hepatitis C
• 6.5 Alcoholic Liver Disease
• 6.6 Genetic Disorders
• 6.7 Autoimmune Hepatitis

7 Global Liver Fibrosis Treatment Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Online Pharmacies
• 7.4 Retail Pharmacies

8 Global Liver Fibrosis Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 Bristol-Myers Squibb Company
• 10.3 Akero Therapeutics
• 10.4 Hepion Pharmaceuticals
• 10.5 Alentis Therapeutics
• 10.6 Inventiva Pharma
• 10.7 Alnylam Pharmaceuticals
• 10.8 Johnson & Johnson
• 10.9 Astellas Pharma Inc.
• 10.10 Novartis AG
• 10.11 Boehringer Ingelheim
• 10.12 Merck & Co., Inc.
• 10.13 Pfizer Inc.
• 10.14 Sanofi AG
• 10.15 Vertex Pharmaceuticals Incorporated
• 10.16 Galectin Therapeutics, Inc.
• 10.17 Takeda Pharmaceutical Company
• 10.18 Gilead Sciences, Inc.
• 10.19 Madrigal Pharmaceuticals, Inc.
• 10.20 GlaxoSmithKline PLC